Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3B | O95264 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | HTR3A | P46098 | 1/20 | 0.30 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3401334 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL6348949 | 0.98 | — | — | |
| SCHEMBL557849 | 0.86 | — | — | |
| Hydrochloric Acid SCHEMBL13737719 | 0.84 | CHRNA7 (0.34) | CHRM3 | |
| SCHEMBL8303605 | 0.83 | SLC18A3 (0.31) | — | |
| SCHEMBL7951217 | 0.80 | — | — | |
| SCHEMBL1297748 | 0.80 | — | — | |
| SCHEMBL7947695 | 0.80 | — | — | |
| SCHEMBL14490824 | 0.74 | — | — | |
| SCHEMBL557562 | 0.72 | CHRNB2 (0.32) | CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050137225-A1 | Aza-bridged bicyclic amine derivatives for use as novel cholinergic receptor ligands | KOHN HAROLD (US) | 2005-06-23 | — | — | US | claimed |
| WO-2004013143-A2 | AZA-BRIDGED BICYCLIC AMINE DERIVATIVES FOR USE AS NOVEL CHOLINERGIC RECEPTOR LIGANDS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2004-02-12 | — | — | WO | claimed |
| US-20040029911-A1 | Aza-bridged bicyclic amine derivatives for use as novel cholinergic receptor ligands | NORTH CAROLINA, UNIVERSITY OF, THE | 2004-02-12 | — | — | US | claimed |
| EP-3658546-B1 | INDOLE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2022-10-26 | — | — | EP | disclosed |
| EP-3658546-A1 | INDOLE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2020-06-03 | — | — | EP | disclosed |
| US-10654828-B2 | Indole derivatives and uses thereof | NOVARTIS AG (CH) | 2020-05-19 | — | — | US | disclosed |
| US-20190055219-A1 | INDOLE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2019-02-21 | — | — | US | disclosed |
| WO-2019021059-A1 | INDOLE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2019-01-31 | — | — | WO | disclosed |
| US-9983218-B2 | Indole and indoline derivatives and methods of use thereof | ABBVIE INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20180024144-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-9625475-B2 | Indole and indoline derivatives and methods of use thereof | ABBVIE INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-5464842-A | Azabicyclo oxime and amine cholinergic agents and methods of treatment | WARNER-LAMBERT COMPANY (US) | 1995-11-07 | — | — | US | disclosed |
| US-5464842-A | Azabicyclo oxime and amine cholinergic agents and methods of treatment | WARNER-LAMBERT COMPANY (US) | 1995-11-07 | — | — | US | disclosed |
| EP-0625979-A1 | AZABRICYCLIC COMPOUNDS AS CALCIUM CHANNEL ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-11-30 | — | — | EP | disclosed |
| US-5318978-A | Azabicyclo oxime and amine cholinergic agents and methods of treatment | WARNER-LAMBERT COMPANY (US) | 1994-06-07 | — | — | US | disclosed |
| EP-0337547-B1 | Spirocyclic compounds incorporating five-membered rings with two heteroatoms | MERCK SHARP & DOHME (GB) | 1994-03-02 | — | — | EP | disclosed |
| WO-1993015073-A1 | AZABRICYCLIC COMPOUNDS AS CALCIUM CHANNEL ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1993-08-05 | — | — | WO | disclosed |
| WO-1993008191-A1 | AZABICYCLO OXIME AND AMINE CHOLINERGIC AGENTS AND METHODS OF TREATMENT | WARNER-LAMBERT COMPANY (US) | 1993-04-29 | — | — | WO | disclosed |
| US-4940703-A | Spirocyclic compounds incorporating five-membered rings with two heteroatoms for treating psychotic disorders, etc. | MERCK SHARP & DOHME LIMITED (GB) | 1990-07-10 | — | — | US | disclosed |
| EP-0337547-A1 | Spirocyclic compounds incorporating five-membered rings with two heteroatoms | MERCK SHARP & DOHME LTD. (GB) | 1989-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137225-A1 | Aza-bridged bicyclic amine derivatives for use as novel cholinergic receptor ligands | CHRNA5, CHRNG, CHRNA4 | HTR3B 182/4885ADRA2A 76/4885KCNE1 691/4885 |
| US-20180024144-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | HTR3B 19/4885ADRA2A 138/4885KCNE1 3027/4885 |
| US-20190055219-A1 | INDOLE DERIVATIVES AND USES THEREOF | MYLK2, MYOF, MUSK | HTR3B 1051/4885ADRA2A 2134/4885KCNE1 4663/4885 |
| US-20040029911-A1 | Aza-bridged bicyclic amine derivatives for use as novel cholinergic receptor ligands | CHRNA5, CHRNG, CHRNA4 | HTR3B 182/4885ADRA2A 76/4885KCNE1 691/4885 |
| US-10654828-B2 | Indole derivatives and uses thereof | MYLK2, MYOF, MUSK | HTR3B 1051/4885ADRA2A 2134/4885KCNE1 4663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.